An assessment of S-carboxymethylcysteine in the treatment of chronic bronchitis.
D000328:Adult; D000368:Aged; D000600:Amino Acids, Dicarboxylic / Q000627:therapeutic use; D000603:Amino Acids, Sulfur / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001991:Bronchitis / Q000188:drug therapy*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003545:Cysteine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005100:Expectorants / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011009:Pneumoconiosis / Q000150:complications; D012744:Sex Ratio; D013223:Statistics as Topic; D013997:Time Factors
D000600:Amino Acids, Dicarboxylic; D000603:Amino Acids, Sulfur; D000900:Anti-Bacterial Agents; D005100:Expectorants; D010919:Placebos; D003545:Cysteine